TD Cowen Maintains Coherus BioSciences(CHRS.US) With Buy Rating
Strategic Divestment and Ambitious Targets Support Coherus Biosciences' Buy Rating
H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Express News | Coherus BioSciences Shares Are Trading Lower. The Company Reported Q1 Financial Results
Coherus BioSciences | 10-Q: Q1 2025 Earnings Report
Coherus BioSciences | 8-K: Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio With CHS-114 and LOQTORZI Developments
Express News | Coherus BioSciences Q1 Sales USD 7.599 Million Vs. IBES Estimate USD 54.7 Million
Express News | Coherus BioSciences Q1 Adjusted Net Income USD -40.9 Million
Express News | Coherus BioSciences Q1 Operating Income USD -45.435 Million
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Press Release: Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Coherus BioSciences 1Q Loss $56.6M >CHRS
Here Are the Major Earnings After the Close Today
Earnings Scheduled For May 12, 2025
COHERUS BIOSCIENCES Earnings Preview: Recent $CHRS Insider Trading, Hedge Fund Activity, and More
Earnings Preview: Coherus BioSciences
Earnings Preview: CHRS to Report Financial Results Post-market on May 12
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025